Note: The following publications may contain information that is not consistent with the approved prescribing information for resmetirom. These publications do not constitute a recommendation for use outside of country-specific labeling.
If you do not have personal or institutional subscriptions for a particular article, please submit a medical information request. Transfer of value tracking may apply.
Nat Med. 2023;29(11):2919-2928. doi:10.1038/s41591-023-02603-1
Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial
Stephen A Harrison, Rebecca Taub, Guy W Neff, K Jean Lucas, Dominic Labriola, Sam E Moussa, Naim Alkhouri, Mustafa R BashirOctober 16, 2023
N Engl J Med. 2024;390(6):497-509. doi:10.1056/NEJMoa2309000
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis
Stephen A Harrison, Pierre Bedossa, Cynthia D Guy, Jörn M Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Sam E Moussa, Guy W Neff, Mary E Rinella, Quentin M Anstee, Manal F Abdelmalek, Zobair Younossi, Seth J Baum, Sven Francque, Michael R Charlton, Philip N Newsome, Nicolas Lanthier, Ingolf Schiefke, Alessandra Mangia, Juan M Pericàs, Rashmee Patil, Arun J Sanyal, Mazen Noureddin, Meena B Bansal, Naim Alkhouri, Laurent Castera, Madhavi Rudraraju, Vlad Ratziu 1; MAESTRO-NASH InvestigatorsFebruary 7, 2024
Aliment Pharmacol Ther. 2024;59(1):51-63. doi:10.1111/apt.17734
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis
Stephen A Harrison, Vlad Ratziu, Quentin M Anstee, Mazen Noureddin, Arun J Sanyal, Jörn M Schattenberg, Pierre Bedossa, Mustafa R Bashir, David Schneider, Rebecca Taub, Meena Bansal, Kris V Kowdley, Zobair M Younossi, Rohit LoombaOctober 2, 2023
Resmetirom is currently only approved in the United States.